Last reviewed · How we verify

Lenvatinib + losartan

Second Affiliated Hospital of Xi'an Jiaotong University · FDA-approved active Small molecule

Lenvatinib + losartan is a Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University. It is currently FDA-approved for Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component), Hepatocellular carcinoma (lenvatinib component), Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients.

Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to suppress tumor angiogenesis and growth, while losartan blocks angiotensin II receptors to manage hypertension and potentially reduce treatment-related cardiovascular toxicity.

Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to suppress tumor angiogenesis and growth, while losartan blocks angiotensin II receptors to manage hypertension and potentially reduce treatment-related cardiovascular toxicity. Used for Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component), Hepatocellular carcinoma (lenvatinib component), Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients.

At a glance

Generic nameLenvatinib + losartan
SponsorSecond Affiliated Hospital of Xi'an Jiaotong University
Drug classMulti-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist
TargetFGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Lenvatinib is a multi-targeted kinase inhibitor that suppresses tumor vasculature and cancer cell proliferation by inhibiting FGFR, VEGFR, and RET signaling. Losartan, an angiotensin II receptor antagonist, is co-administered to mitigate hypertension and other cardiovascular adverse effects commonly associated with lenvatinib monotherapy. This combination approach aims to improve tolerability while maintaining anti-tumor efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lenvatinib + losartan

What is Lenvatinib + losartan?

Lenvatinib + losartan is a Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist drug developed by Second Affiliated Hospital of Xi'an Jiaotong University, indicated for Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component), Hepatocellular carcinoma (lenvatinib component), Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients.

How does Lenvatinib + losartan work?

Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to suppress tumor angiogenesis and growth, while losartan blocks angiotensin II receptors to manage hypertension and potentially reduce treatment-related cardiovascular toxicity.

What is Lenvatinib + losartan used for?

Lenvatinib + losartan is indicated for Radioactive iodine-refractory differentiated thyroid cancer (lenvatinib component), Hepatocellular carcinoma (lenvatinib component), Hypertension management and cardiotoxicity mitigation in lenvatinib-treated patients.

Who makes Lenvatinib + losartan?

Lenvatinib + losartan is developed and marketed by Second Affiliated Hospital of Xi'an Jiaotong University (see full Second Affiliated Hospital of Xi'an Jiaotong University pipeline at /company/second-affiliated-hospital-of-xi-an-jiaotong-university).

What drug class is Lenvatinib + losartan in?

Lenvatinib + losartan belongs to the Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist class. See all Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist drugs at /class/multi-targeted-tyrosine-kinase-inhibitor-angiotensin-ii-receptor-antagonist.

What development phase is Lenvatinib + losartan in?

Lenvatinib + losartan is FDA-approved (marketed).

What are the side effects of Lenvatinib + losartan?

Common side effects of Lenvatinib + losartan include Hypertension, Diarrhea, Fatigue, Nausea, Decreased appetite, Proteinuria.

What does Lenvatinib + losartan target?

Lenvatinib + losartan targets FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan) and is a Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist.

Related